Compare Stocks: TNYA, MDXG, AVTE, and NVCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$21.70 +1.6%	$19.64	$89.95 ▼ $99.05	$628.97M	0.95	53,591 shs	1.27 million shs
MDXG MiMedx Group	$4.15 -0.4%	$3.96	$3.03 ▼ $7.97	$604.18M	1.45	1.33 million shs	332,899 shs
NVCT Nuvectis Pharma	$18.86 -2.1%	$17.02	$5.55 ▼ $29.27	$499.03M	-0.26	164,622 shs	45,874 shs
TNYA Tenaya Therapeutics	$0.76 -3.0%	$0.77	$0.53 ▼ $2.35	$166.66M	2.83	3.74 million shs	683,760 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	+11.49%	+8.38%	-0.74%	-15.04%	+209.87%
MDXG MiMedx Group	-2.58%	-1.59%	+2.21%	+12.74%	-40.32%
NVCT Nuvectis Pharma	-4.18%	-6.91%	-1.88%	+86.63%	+179.13%
TNYA Tenaya Therapeutics	+5.81%	+6.75%	-9.33%	-7.51%	+12.84%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$21.70 +1.6%	$19.64	$89.95 ▼ $99.05	$628.97M	0.95	53,591 shs	1.27 million shs
MDXG MiMedx Group	$4.15 -0.4%	$3.96	$3.03 ▼ $7.97	$604.18M	1.45	1.33 million shs	332,899 shs
NVCT Nuvectis Pharma	$18.86 -2.1%	$17.02	$5.55 ▼ $29.27	$499.03M	-0.26	164,622 shs	45,874 shs
TNYA Tenaya Therapeutics	$0.76 -3.0%	$0.77	$0.53 ▼ $2.35	$166.66M	2.83	3.74 million shs	683,760 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	+11.49%	+8.38%	-0.74%	-15.04%	+209.87%
MDXG MiMedx Group	-2.58%	-1.59%	+2.21%	+12.74%	-40.32%
NVCT Nuvectis Pharma	-4.18%	-6.91%	-1.88%	+86.63%	+179.13%
TNYA Tenaya Therapeutics	+5.81%	+6.75%	-9.33%	-7.51%	+12.84%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
MDXG MiMedx Group	2.71	Moderate Buy	$8.50	105.07% Upside
NVCT Nuvectis Pharma	2.33	Hold	$35.00	85.58% Upside
TNYA Tenaya Therapeutics	2.86	Moderate Buy	$4.00	425.62% Upside

Current Analyst Ratings Breakdown

Latest TNYA, MDXG, AVTE, and NVCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2026	TNYA Tenaya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/6/2026	NVCT Nuvectis Pharma	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$33.00
7/6/2026	NVCT Nuvectis Pharma	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $33.00
7/2/2026	TNYA Tenaya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/22/2026	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.00 ➝ $39.00
6/12/2026	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$10.00 ➝ $13.00
6/5/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/18/2026	MDXG MiMedx Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
MDXG MiMedx Group	$355.17M	1.70	$0.54 per share	7.71	$1.48 per share	2.80
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.72 per share	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$0.57 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
MDXG MiMedx Group	$48.58M	$0.04	103.65	24.38	N/A	1.76%	12.09%	9.22%	N/A
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-160.35%	-97.98%	N/A
TNYA Tenaya Therapeutics	-$90.60M	-$0.47	N/A	N/A	N/A	N/A	-80.56%	-65.21%	8/12/2026 (Estimated)

Latest TNYA, MDXG, AVTE, and NVCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	TNYA Tenaya Therapeutics	-$0.0683	-$0.20	-$0.1317	-$0.20	$10.00 million	$1.11 million
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A
7/29/2026	Q2 2026 & M&A announcement	MDXG MiMedx Group	-$0.0495	-$0.05	-$0.0005	-$0.10	$63.46 million	$64.36 million
5/6/2026	Q1 2026	TNYA Tenaya Therapeutics	-$0.09	-$0.09	N/A	-$0.09	$7.50 million	$0.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
MDXG MiMedx Group	0.07	5.33	4.79
NVCT Nuvectis Pharma	N/A	2.27	2.27
TNYA Tenaya Therapeutics	N/A	5.75	5.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
MDXG MiMedx Group	79.15%
NVCT Nuvectis Pharma	96.77%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
MDXG MiMedx Group	2.50%
NVCT Nuvectis Pharma	28.55%
TNYA Tenaya Therapeutics	2.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
MDXG MiMedx Group	870	145.76 million	142.12 million	Optionable
NVCT Nuvectis Pharma	8	26.53 million	18.95 million	Not Optionable
TNYA Tenaya Therapeutics	110	217.00 million	211.51 million	Optionable

TNYA, MDXG, AVTE, and NVCT Headlines

Recent News About These Companies

Tenaya Therapeutics (NASDAQ:TNYA) Issues Quarterly Earnings Results

August 5 at 7:55 PM | marketbeat.com

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 5 at 4:05 PM | globenewswire.com

Tenaya Therapeutics (TNYA) Projected to Post Quarterly Earnings on Wednesday

August 5 at 1:56 AM | americanbankingnews.com

Tenaya Therapeutics (TNYA) to Post Earnings on Wednesday

August 5 at 1:55 AM | marketbeat.com

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 4 at 4:05 PM | globenewswire.com

Cours Tenaya Therapeutics, Inc.

July 29, 2026 | zonebourse.comZ

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Moderate Buy" by Brokerages

July 17, 2026 | marketbeat.com

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 14, 2026 | globenewswire.com

Tenaya Therapeutics (NASDAQ:TNYA) Trading Down 3.9% - What's Next?

July 14, 2026 | marketbeat.com

Tenaya Therapeutics (TNYA) Slides to $0.86 as Bearish Pressure Tests Support - Order Block

July 13, 2026 | donanimhaber.comD

Tenaya Names Eric Hyllengren as CFO

June 29, 2026 | marketwatch.com

Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer

June 29, 2026 | globenewswire.com

Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript

June 5, 2026 | seekingalpha.com

Analysts Are Bullish on Top Healthcare Stocks: Ligand Pharma (LGND), Tenaya Therapeutics (TNYA)

June 5, 2026 | theglobeandmail.com

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac ...

June 4, 2026 | finance.yahoo.com

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms

June 3, 2026 | globenewswire.com

Tenaya Therapeutics to Report Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 Gene Therapy for HCM on June 3, 2026

June 2, 2026 | quiverquant.comQ

Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

June 2, 2026 | globenewswire.com

Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026

May 29, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Knight Therapeutics (OtherKHTRF) and TScan Therapeutics (TCRX)

May 25, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: ImmunityBio (IBRX) and Tenaya Therapeutics (TNYA)

May 20, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA, MDXG, AVTE, and NVCT Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$21.70 +0.35 (+1.64%)

As of 08/5/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

MiMedx Group NASDAQ:MDXG

$4.14 -0.02 (-0.36%)

As of 12:09 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Nuvectis Pharma NASDAQ:NVCT

$18.86 -0.40 (-2.08%)

As of 12:08 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Tenaya Therapeutics NASDAQ:TNYA

$0.76 -0.02 (-3.02%)

As of 12:07 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNYA, MDXG, AVTE, and NVCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNYA, MDXG, AVTE, and NVCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNYA, MDXG, AVTE, and NVCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA, MDXG, AVTE, and NVCT Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

MiMedx Group NASDAQ:MDXG

Nuvectis Pharma NASDAQ:NVCT

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNYA, MDXG, AVTE, and NVCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNYA, MDXG, AVTE, and NVCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNYA, MDXG, AVTE, and NVCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA, MDXG, AVTE, and NVCT Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

MiMedx Group NASDAQ:MDXG

Nuvectis Pharma NASDAQ:NVCT

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools